CSL Aims to Improve Efficiency in Blood Plasma Business Introduction CSL, one of the largest biotech companies in Australia with a market value of over $130 billion, is looking to enhance the efficiency of its blood plasma business in the face of rising costs and foreign currency fluctuations. While inflationary pressures have impacted CSL‘s full-year […]